Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2018 | Thoughts on the use of MRD in CLL

Daniel Catovsky • 25 Oct 2018
ERIC 2018
Chronic Lymphocytic Leukemia Leukemia

Daniel Catovsky, MD, DSc, FRCP, FRCPath, FMedSci, of the Institute of Cancer Research, London, UK, gives us his thoughts on the use of measurable residual disease testing (MRD) in the field of chronic lymphocytic leukemia (CLL), from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.

More from Daniel Catovsky

1:49
The future of CLL: managing new toxicities and improved categorization
Daniel Catovsky • 25 Oct 2018
2:21
UK-based CLL clinical trials to look forward to
Daniel Catovsky • 25 Oct 2018

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals